28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
According to the analysis of the GBD database in 2021, the deaths, DALYs, incidence, and prevalence of ADOD increased by 297.34 %, 249.54 %, 244.73 %, and 250.44 % in Asia from 1990 to 2021. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
T2DM is one of the strong risk factors of ADRD but genetic T2DM effect does not contribute to ADRD risk. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From 356 participants, 104 were MCI-C, whereas 252 were MCI-NC. 5 key findings →
Participants: 356 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up period of 10.44 years, 725 participants developed incident dementia. 5 key findings →
Participants: 104,572 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 289,649 included participants, 137,480 (47.5 %) were male, and the mean age was 56.6 ± 8.1 years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The disease burden of ADD in China is heavier than in most countries and regions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings of this study suggest that predictive modeling could inform patients and clinicians about ASCVD at risk for dementia. 3 key findings →
Participants: 29,561 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning models consistently outperformed conventional approach. 5 key findings →
Participants: 38,746 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Predictive performance was comparable across algorithms, with R² ranging from 0.201 to 0.361, highest in the MCI_All dataset. 5 key findings →
Design: longitudinal study Participants: 4,958 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Metabolomics has been associated with cognitive decline and dementia, but the relationship between metabolites and brain aging remains unclear. 4 key findings →
Participants: 17,770 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 1616 participants (AD = 1498, bvFTD = 118), all algorithms achieved high accuracy (80% to 90%) and discriminatory ability (AUC = 0.89 to 0.95). 5 key findings →
Participants: 1,616 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Level 3 model achieved high classification performance (AUC: 93.98%), and the Level 1 model achieved comparable performance (AUC: 91.53%). 5 key findings →
Participants: 31,081 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significant alterations were observed in 7 lipid classes and 65 specific lipid species in DLB compared to AD. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Depression was a strong risk factor for incident dementia with an OR of 1.76 (95% CI 1.63 to 1.90), a relationship which was found to be specific to depression rather than commonly proposed confounders. 5 key findings →
Participants: 557 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of the 1216 cases reported, Alzheimer's disease (60.5%) was the most common subtype, followed by vascular dementia (24.5%). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dementia affects approximately 55 million people globally, with modifiable risk factors contributing significantly to its prevalence. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This cross-sectional study examines data for participants in the Alzheimer Biomarker Consortium–Down Syndrome study to gauge the concordance of clinical and biological Alzheimer disease staging. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In a heterogeneous autopsy sample, AD and LB pathology both contribute to cholinergic basal forebrain degeneration whereas hippocampus atrophy is more specifically related to AD pathology. 4 key findings →
Participants: 248 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson's disease and synucleinopathies. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Glymphatic activity in bvFTD correlated strongly with vascular dysfunction and astrocytic activation, and was associated with brain changes and clinical severity. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma biomarkers are promising tools for the screening and diagnosis of dementia in clinical settings. 1 key finding →
Participants: 108 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Moreover, a theoretical model proposes that frontotemporal dementia manifestations result from a deficit in goal-directed behaviour, which may be related to altered dopamine control of the frontostriatal circuitry. 4 key findings →
Participants: 139 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundDifferentiating neurodegenerative diseases can be difficult in the clinical setting. 2 key findings →
Participants: 2,751 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.205; p = 0.651); and between typical (21%) and atypical (11%) subgroups (Fisher's test, p = 0.184). 5 key findings →
Participants: 84 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal dementia (FTD) is a neurodegenerative disorder primarily affecting the frontal and temporal lobes, leading to significant impairments in executive function, social behavior, and emotional regulation. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →